Cargando…
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies
The drug pipeline for the treatment of inflammatory bowel disease (IBD) has dramatically expanded over the last two decades, and it is expected to further grow in the upcoming years with the introduction of new agents with different mechanisms of action. However, such an increase of therapeutic opti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697479/ https://www.ncbi.nlm.nih.gov/pubmed/36431194 http://dx.doi.org/10.3390/jcm11226717 |
_version_ | 1784838573674987520 |
---|---|
author | Pugliese, Daniela Onali, Sara Privitera, Giuseppe Armuzzi, Alessandro Papi, Claudio |
author_facet | Pugliese, Daniela Onali, Sara Privitera, Giuseppe Armuzzi, Alessandro Papi, Claudio |
author_sort | Pugliese, Daniela |
collection | PubMed |
description | The drug pipeline for the treatment of inflammatory bowel disease (IBD) has dramatically expanded over the last two decades, and it is expected to further grow in the upcoming years with the introduction of new agents with different mechanisms of action. However, such an increase of therapeutic options needs to be paralleled with an appropriate development of research to help physicians in the decision-making process when choosing which drug to prescribe. On the population level, comparative effectiveness research (CER) is intended to explore and identify relevant differences—in terms of both efficacy and safety outcomes—amongst different therapeutic regimens and/or strategies, in order to find the correct placement for each treatment in the therapeutic algorithm. CER revolves around three cornerstones: network meta-analyses, head-to-head trials and real-world studies, each of which has specific pros and cons, and can therefore offer answers to different questions. In this review, we aim to provide an overview on the methodological features specific to each of these research approaches, as well as to illustrate the main findings coming from CER on IBD target therapies (i.e., biologics and small molecules) and to discuss their appropriate interpretation. |
format | Online Article Text |
id | pubmed-9697479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96974792022-11-26 Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies Pugliese, Daniela Onali, Sara Privitera, Giuseppe Armuzzi, Alessandro Papi, Claudio J Clin Med Review The drug pipeline for the treatment of inflammatory bowel disease (IBD) has dramatically expanded over the last two decades, and it is expected to further grow in the upcoming years with the introduction of new agents with different mechanisms of action. However, such an increase of therapeutic options needs to be paralleled with an appropriate development of research to help physicians in the decision-making process when choosing which drug to prescribe. On the population level, comparative effectiveness research (CER) is intended to explore and identify relevant differences—in terms of both efficacy and safety outcomes—amongst different therapeutic regimens and/or strategies, in order to find the correct placement for each treatment in the therapeutic algorithm. CER revolves around three cornerstones: network meta-analyses, head-to-head trials and real-world studies, each of which has specific pros and cons, and can therefore offer answers to different questions. In this review, we aim to provide an overview on the methodological features specific to each of these research approaches, as well as to illustrate the main findings coming from CER on IBD target therapies (i.e., biologics and small molecules) and to discuss their appropriate interpretation. MDPI 2022-11-13 /pmc/articles/PMC9697479/ /pubmed/36431194 http://dx.doi.org/10.3390/jcm11226717 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pugliese, Daniela Onali, Sara Privitera, Giuseppe Armuzzi, Alessandro Papi, Claudio Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies |
title | Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies |
title_full | Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies |
title_fullStr | Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies |
title_full_unstemmed | Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies |
title_short | Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies |
title_sort | comparative effectiveness research: a roadmap to sail the seas of ibd therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697479/ https://www.ncbi.nlm.nih.gov/pubmed/36431194 http://dx.doi.org/10.3390/jcm11226717 |
work_keys_str_mv | AT pugliesedaniela comparativeeffectivenessresearcharoadmaptosailtheseasofibdtherapies AT onalisara comparativeeffectivenessresearcharoadmaptosailtheseasofibdtherapies AT priviteragiuseppe comparativeeffectivenessresearcharoadmaptosailtheseasofibdtherapies AT armuzzialessandro comparativeeffectivenessresearcharoadmaptosailtheseasofibdtherapies AT papiclaudio comparativeeffectivenessresearcharoadmaptosailtheseasofibdtherapies |